266. Familial mediterranean fever Clinical trials / Disease details
Clinical trials : 28 / Drugs : 24 - (DrugBank : 6) / Drug target genes : 14 - Drug target pathways : 59
Showing 1 to 10 of 28 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05190991 (ClinicalTrials.gov) | October 5, 2021 | 3/11/2021 | Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchi ... | An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Pre ... | Familial Mediterranean Fever;FMF | Biological: RPH-104 | R-Pharm International, LLC | Atlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management 365 LLC Atlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management ... | Recruiting | 18 Years | 80 Years | All | 60 | Phase 2 | Armenia;Georgia;Russian Federation |
2 | NCT04478409 (ClinicalTrials.gov) | July 21, 2021 | 16/7/2020 | Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 | Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 | Familial Mediterranean Fever;MEFV Gene Mutation | Biological: one additional blood sample during a planned blood test | Hospices Civils de Lyon | NULL | Recruiting | 4 Years | N/A | All | 160 | France | |
3 | JPRN-UMIN000032557 | 2018/09/01 | 30/05/2018 | An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance An open-label continuation trial of tocilizumab for familial Mediterranean feverwith colchicine inef ... | An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance - An open-label continuation trial of tocilizumab for familial Mediterranean fever An open-label continuation trial of tocilizumab for familial Mediterranean feverwith colchicine inef ... | familial Mediterranean fever | Tocilizumab | Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasak ... | NULL | Complete: follow-up continuing | 12years-old | Not applicable | Male and Female | 24 | Not selected | Japan |
4 | NCT03563300 (ClinicalTrials.gov) | September 1, 2018 | 24/5/2018 | Gluten-related Disorders in Familial Mediterranean Fever Patients | Gluten-related Disorders in Patients Affected With Familial Mediterranean Fever | Not-celiac Wheat Sensitivity (NCWS);Familial Mediterranean Fever (FMF) | Other: Wheat flour;Other: Placebo Comparator | University of Palermo | NULL | Completed | 18 Years | 65 Years | All | 8 | N/A | Italy |
5 | NCT03446209 (ClinicalTrials.gov) | April 23, 2018 | 11/12/2017 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study Tocilizumab for the Treatment of Familial Mediterranean Fever- A Randomized, Doubleblind, Phase II P ... | Familial Mediterranean Fever | Drug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological saline | University Hospital Tuebingen | NULL | Completed | 18 Years | 64 Years | All | 30 | Phase 2 | Germany |
6 | JPRN-UMIN000028010 | 2018/03/01 | 07/07/2017 | Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant fa ... | Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever - Clinical trial of Tocilizumab for colchicine-resistant familial Mediterranean fever Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant fa ... | familial Mediterranean fever | Tocilizumab Placebo | Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasak ... | NULL | Complete: follow-up complete | 12years-old | Not applicable | Male and Female | 24 | Not selected | Japan |
7 | EUCTR2016-004505-13-DE (EUCTR) | 27/11/2017 | 21/08/2017 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever Tocilizumab for the Treatment of Familial Mediterranean Fever– A randomized, doubleblind, phase II p ... | Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0;Level ... | Trade Name: RoActemra® 20mg/ml Konzentrat INN or Proposed INN: INN-Tocilizumab Other descriptive name: TOCILIZUMAB Trade Name: RoActemra® 20mg/ml Konzentrat INN or Proposed INN: INN-Tocilizumab Other descriptive name: ... | University Hospital Tuebingen | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
8 | NCT03210610 (ClinicalTrials.gov) | October 19, 2017 | 29/6/2017 | Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients | Measurement of Colchicine Levels in the Serum of FMF Patients | FMF;Colchicine Resistance;Colchicine Toxicity | Diagnostic Test: colchicine level measurement | Sheba Medical Center | NULL | Unknown status | 18 Years | N/A | All | 80 | Israel | |
9 | EUCTR2013-004291-35-NL (EUCTR) | 07/10/2014 | 24/07/2014 | Study of efficacy and safety of canakinumab in patients with Hereditary Periodic Fevers | A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reduction and open-label long term treatment epochs A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Peri ... | Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) MedDRA version: 19.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 19.0;Level: LLT;Classification code 10067783;Term: Tumor necrosis factor receptor-associated periodic syndrome;Classification code 10072010;Term: Hyper IgD syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) MedDRA version: 19.0;Level: PT;Classification cod ... | Trade Name: Ilaris Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Canada;Belgium;Denmark;Netherlands;Germany;Japan United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United ... | ||
10 | EUCTR2013-004291-35-GR (EUCTR) | 22/09/2014 | 22/09/2014 | Study of efficacy and safety of canakinumab in patients with Hereditary Periodic Fevers | A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reduction and open-label long term treatment epochs A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Peri ... | Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) MedDRA version: 17.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 17.0;Level: LLT;Classification code 10067783;Term: Tumor necrosis factor receptor-associated periodic syndrome;Classification code 10072010;Term: Hyper IgD syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) MedDRA version: 17.0;Level: PT;Classification cod ... | Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Belgium;Denmark;Germany;Netherlands;Japan United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Israel;United Kingdom;Switzerla ... |